Business Wire

HEALTHCARE-AT-HOME

10.11.2020 10:02:07 CET | Business Wire | Press release

Share
Healthcare at Home Launches Sciensus Rare to Connect Emerging Biotech and Large Pharma Companies With Rare Disease Patients in Europe and Beyond

Healthcare at Home today unveils a dedicated new rare disease medicines services business: Sciensus Rare.

Sciensus Rare launches with two main aims: to ensure that patients and their families have access to the rare disease medicines and care they need, and to help biotech and pharmaceutical companies safely launch and efficiently deliver vital medication, no matter where a patient lives or the regulatory governance of that country.

The business will continue to help emerging, mid-sized, and major biotech and pharmaceutical companies gain market access in Europe and beyond, expanding Healthcare at Home’s existing rare disease and orphan medicines services further geographically and by therapy area, across five main services:

- Clinical trials in the home

- Medicines access

- Bespoke supply chain management

- Patient and family support

- Outcome monitoring in the home

According to Eurostat, the market for rare disease pharmaceutical medicines services is expected to more than double in size over the next few years, growing from €1.6bn in 2018 to €3.3bn in 2025, as the number of products requiring more complex services to support them grows. Sciensus Rare aims to meet the growing demand by creating a unique, science-led approach to help pharmaceutical partners reduce time to market for innovative, high cost, new medicines in a rapidly changing marketplace, helping to eliminate unnecessary costs and inefficiencies in the drug development process.

Gareth Williams, President of Sciensus Rare, said:

“The global pandemic has accelerated the need for bespoke patient-centred services which are required for products in drug development and commercial phases as many rare disease patients can’t or won’t travel long distances to take part in clinical trials away from home.

“Our aim is to help emerging biotech firms which have a strong presence in their home market but little or no international distribution or commercial infrastructure, as well as the established pharma companies seeking access to treatment for patients with unmet needs”.

Sciensus Rare’s services build on Healthcare at Home’s three decades of experience in treating rare disease patients. In that time, the business has treated more than 52,000 patients at home, and collaborated with over 20 rare disease pharmaceutical companies and over 4,000 healthcare providers in mainland Europe. BioMarin, which specialises in developing and commercialising biopharmaceuticals for rare diseases driven by genetic causes, has been working with Healthcare at Home since 2006 and now sees a quarter of its global sales delivered through this model.

Guy Eggleton, Executive Director Sales and Marketing Operations EUMEA, at BioMarin, said:

“Sciensus Rare has tremendous potential to build on its significant experience in rare diseases to become the global expert in helping businesses like ours connect rare disease patients and healthcare providers with effective, innovative new treatments for rare conditions.”

The need to develop and provide access to safe, effective medicines is most acute in rare diseases, many of which are genetic and affect younger patients.

Williams concluded:

“The ‘one size fits all’ approach to rare and orphan managed medication services, with no clear integrator of drug development through to commercial services is now outmoded and redundant. With many new therapies coming to market from a burgeoning pharmaceutical research and development side, it is clear to us that there is a role for a different kind of bespoke managed pharmaceutical services provider that puts the needs of the patient at its heart regardless of where the therapy is in its lifecycle.”

The Sciensus Rare name will replace Healthcare at Home’s Rare Disease Medicines Service.

** ENDS **

NOTES TO EDITORS

About Sciensus Rare ( www.sciensusrare.com )
We believe in making sure every family has access to rare disease medicines and the care they need. No matter where a patient lives or the regulatory governance of that country, we can safely launch and efficiently deliver vital medication and clinical services for families that need it most.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release

Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release

Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release

Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release

With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye